Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients

Background Axitinib is an oral, potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3. We report on data obtained from 18 Japanese patients with advanced solid tumors in two phase I trials that evaluated the safety, pharmacokinetics and antitumor activity...

Full description

Saved in:
Bibliographic Details
Main Authors: Fujiwara, Yutaka, Kiyota, Naomi, Chayahara, Naoko, Suzuki, Akiyuki, Umeyama, Yoshiko, Mukohara, Toru, Minami, Hironobu
Format: Artigo
Language:Inglês
Published: Springer US 2011
Subjects:
Phase I Studies
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3348450/
https://ncbi.nlm.nih.gov/pubmed/21301929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9637-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items